BioChatter: making large language models accessible for biomedical research
Introducing an open-source large language model (LLM) framework designed for custom biomedical research.
SCIENCE & TECHNOLOGY2025
research-highlightsscience-technology
Cancer drug resistance causes and categories identified
Researchers uncover that DNA changes that cause cancer drug resistance can be grouped into four categories, and identify possible new therapeutic targets.
2024
announcements
Why clinical trials stop: the role of genetics
Using machine learning to analyse the genetic factors behind early clinical trial termination, researchers find a link between genetic evidence and trial outcome.
SCIENCE & TECHNOLOGY2024
research-highlightsscience-technology
We are EMBL: Melanie Schneider on changing career trajectory
ARISE fellow Melanie Schneider shares how she uncovered a new interest in research infrastructures and supporting discovery.
PEOPLE & PERSPECTIVES2024
people-perspectivesperspectives
MSD joins the Open Targets consortium
MSD joins as the latest partner in the Open Targets consortium, enhancing the initiative’s collaborative efforts in drug discovery.
EMBL ANNOUNCEMENTS2024
announcementsembl-announcements
Deciphering the data deluge: how large language models are transforming scientific data curation
Large language models are changing the way we carry out scientific data curation, annotation, and research, setting the stage for a more efficient understanding of scientific literature
2023
technology-and-innovation
Welcome: David Hulcoop
David Hulcoop discusses how his experience bridging organisational cultures will help address critical challenges in drug discovery and target selection at Open Targets.
LAB MATTERSPEOPLE & PERSPECTIVES2023
announcementslab-matterspeople-perspectives
EMBL-EBI’s new building set to support data growth and innovative partnerships
Construction begins on EMBL-EBI's new building named after Janet Thornton.
EMBL ANNOUNCEMENTSLAB MATTERS2023
announcementsembl-announcementslab-matters
David Hulcoop appointed as Open Targets Director
Coming from a pharmaceutical industry background, David Hulcoop is set to take over as Executive Director of the public-private partnership Open Targets.
EMBL ANNOUNCEMENTS2023
announcementsembl-announcements
ProtVar: understanding missense variation in humans
A new tool for the interpretation of missense variation in humans – ProtVar – will help enable drug discovery.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
A human interactome to prioritise drug discovery
Researchers create a network of interacting proteins – or interactome – to aid drug discovery.
2023
research-highlightsscience
Machine learning to identify and prioritise drug targets
Open Targets is using artificial intelligence and machine learning to identify and prioritise drug targets.
SCIENCE & TECHNOLOGY2023
sciencescience-technologytechnology-and-innovation
Open Targets consortium welcomes Genentech as newest member
Open Targets announces that Genentech will become the seventh partner in the drug discovery and validation consortium.
2022
announcementsscience
Pfizer joins the Open Targets consortium
Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner.
CONNECTIONS2022
announcementsconnectionsscience
The human genome, data sharing, and drug discovery: a career profile with Ian Dunham
Ian Dunham walks us through his career so far including working on the human genome project, seeing his work on the cover of Nature and his current role as Director of Open Targets.
LAB MATTERSPEOPLE & PERSPECTIVES2021
lab-matterspeople-perspectives
The PROTACtable genome – a new route to drug discovery
Researchers establish a framework for identifying new drugs capable of exploiting a cell’s own machinery.
SCIENCE & TECHNOLOGY2021
sciencescience-technology
Welcome: Ellie McDonagh
Open Targets welcomes new Informatics Science Director
LAB MATTERSPEOPLE & PERSPECTIVES2020
lab-matterspeople-perspectives
Programming: language
How computer processing of human language is harnessed by EMBL scientists
SCIENCE & TECHNOLOGY2019
sciencescience-technology
Twenty years of EMBLEM
Reflecting on 20 years of EMBLEM
LAB MATTERS2019
lab-matters
New Open Targets Director appointed
New director drives drug discovery partnership forward
LAB MATTERSPEOPLE & PERSPECTIVES2019
lab-matterspeople-perspectives
No results found